Sito Bio(SZ:300583)2023-07-30 16:00Financial Performance - The company's operating revenue for the first half of 2023 reached ¥663,655,673.27, an increase of 4.31% compared to ¥636,242,960.65 in the same period last year[21]. - Net profit attributable to shareholders was ¥59,967,581.48, representing an 85.43% increase from ¥32,339,106.58 in the previous year[21]. - Basic and diluted earnings per share increased to ¥0.55, up 83.33% from ¥0.30 in the previous year[21]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which reached ¥37,125,683.51, a 20.73% increase from ¥30,750,102.42 in the previous year[21]. - The company achieved a net profit of CNY 59,967,581.48 for the first half of 2023, with a parent company net profit of CNY 40,670,451.84[116]. - The company reported a total comprehensive income of CNY 63,455,115.72 for the first half of 2023, compared to CNY 30,385,506.16 in the previous year[199]. - The company's revenue for the reporting period reached ¥663,655,673.27, representing a year-on-year increase of 4.31% compared to ¥636,242,960.65 in the same period last year[58]. - The gross profit margin for steroid drug raw materials was 29.15%, showing an increase of 4.95% year-on-year[61]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥117,369,579.22, a decline of 164.23% compared to ¥182,721,185.87 in the same period last year[21]. - Cash and cash equivalents increased by 190.15% to ¥196,875,958.76, up from ¥67,853,561.20, primarily due to the influx of funds from the capital increase[58]. - The company's total assets as of June 30, 2023, were ¥3,506,106,963.83, reflecting a growth of 17.04% from ¥2,995,140,143.52 at the end of the previous year[22]. - The company's current assets reached CNY 1,625,846,289.28 as of June 30, 2023, compared to CNY 1,139,941,599.15 at the beginning of the year, indicating a rise of about 42.6%[191]. - The total liabilities increased to CNY 1,421,629,861.62 from CNY 1,224,800,344.70, reflecting a growth of approximately 16.1%[193]. - The company's equity attributable to shareholders rose to CNY 2,027,241,953.83 as of June 30, 2023, up from CNY 1,720,136,902.94, marking an increase of around 17.8%[193]. Investments and Projects - The company plans to distribute 6 new shares for every 10 shares held, utilizing capital reserves[6]. - Research and development investment increased by 41.91% to ¥27,913,511.71, up from ¥19,670,389.92, aimed at accelerating project progress[58]. - The total investment during the reporting period was CNY 59,966,853.47, representing a 20.09% increase compared to CNY 49,933,124.73 in the same period last year[70]. - The company has committed to producing 180 tons of dihydroxy yellow ketone, with ongoing developments in this area[84]. - The company plans to invest 270 million yuan into a new project for steroid intermediates and raw materials, with a total investment of 450.91 million yuan[90]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on steroid drugs, and is positioned in the upper-middle stream of the pharmaceutical supply chain[32]. - The company is actively pursuing international market expansion, evidenced by the issuance of a European pharmacopoeia suitability certificate for one of its raw materials[38]. - The company has established long-term strategic partnerships with major pharmaceutical companies, enhancing its market position and brand recognition[53]. - The company is focused on upgrading its entire industry chain, linking intermediates, raw materials, and formulations to improve cost and quality control[55]. - The company is committed to enhancing its research and development capabilities to maintain a leading position in the industry[106]. Environmental Compliance - The company emphasizes environmental protection and has implemented measures to comply with strict safety and environmental regulations[107]. - The company has implemented a wastewater treatment system that combines advanced physical and chemical processes, including multi-effect evaporation and Fenton oxidation, to ensure compliance with environmental standards[124]. - The company has classified and treated exhaust gases from various processes using methods such as alkaline spraying and catalytic oxidation, ensuring stable emissions that meet regulatory standards[125]. - The company has established a comprehensive waste management system, including separate storage for hazardous waste and measures to prevent leakage[126]. - The company has committed to zero emissions of various industrial solid wastes, ensuring no discharge into the external environment[128]. Shareholder Information - The company plans to increase its total share capital by 71,138,297 shares through a capital reserve transfer, resulting in a total share capital of 189,702,126 shares[116]. - The total number of shares outstanding is now 118,563,829, with 104,387,067 shares being unrestricted[169]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of the shares, totaling 27,060,864 shares[179]. - The company has a six-month lock-up period for the newly issued shares[176]. - The company’s major shareholders have pledged a significant portion of their shares, with the first major shareholder pledging 80% of their holdings[181].